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Abstract
Background: Enterovirus 71 (EV71) is a viral pathogen that belongs to the Picornaviridae family, EV71-infected children 
can develop severe neurological complications leading to rapid clinical deterioration and death.
Results: In this study, several monoclonal antibodies (MAbs) were produced by immunizing mice with the inactived 
EV71 Henan (Hn2) virus strain. The isolated MAbs were characterised by in vitro neutralizing analysis and peptide ELISA. 
ELISA assay showed that the neutralizing monoclonal antibody 4E8 specifically reacted with synthetic peptides which 
contain amino acid 240-250 and 250-260 of EV71 VP1. The in vivo protection assay showed that 4E8 can protect two-
day-old BALB/c mice against the lethal challenge of EV71 virus.
Conclusion: The MAb 4E8 could be a promising candidate to be humanized and used for treatment of EV71 infection.
Background
Enterovirus 71 (EV71) is a viral pathogen within the
Picornaviridae family and causes clinical diseases in
humans with manifestations such as herpangina, aseptic
meningitis, encephalitis, pulmonary edema and hand,
foot and mouth disease (HFMD). EV71-infected children
can develop severe neurological complications that lead
to rapid clinical deterioration and death [1]. Since the
first instances in 1969 [2], several large epidemics of
HFMD have been reported in the Asia-Pacific region,
especially in Southeast Asia [3-6]. In China, between
1999-2009, HFMD outbreaks caused by EV71 have
affected more than 500,000 young children and resulted
in more than 200 deaths in cities, such as Beijing, Shen-
zhen, Guangdong [7-9]. In fact, after the eradication of
the poliovirus [10], EV71 has been regarded as the most
important neurotropic enterovirus.
Since there is no EV71 vaccine available and treatment
is very limited, a humanized monoclonal antibody might
be a viable treatment option against EV71 infection in
humans. Anti-EV71 MAbs which have specificity and
neutralizing activity could be a promising candidate to be
humanized and used for treatment of EV71 infection.
EV71 contains a positive-stranded RNA enclosed by
capsid proteins VP1, VP2, VP3 and VP4. VP1 is com-
posed of 297 amino acids and has been shown to be
immunogenic [11]. It has been reported that the synthetic
peptides SP55 and SP70, which contain amino acids 163-
177 and 208-222 of VP1, respectively, can elicit neutraliz-
ing antibody against EV71 infection [12,13]. Also, immu-
nization using a recombinant VP1 protein of EV71 was
shown to confer protection against lethal EV71 infection
in newborn mice, indicating that VP1 contains important
antigenic sites that contribute to the neutralization of the
virus [14,15].
In this study, we generated several MAbs by immuniz-
ing mice with purified EV71 virus, strain Henan2 (Hn2).
These MAbs were characterised by in vitro neutralizing
analysis and peptide ELISA. We identified a monoclonal
antibody, clone 4E8 with strong neutralizing activity
against EV71. The MAb 4E8 specifically reacted with
synthetic peptides which containing amino acids 240-250
and 250-260 of VP1 by ELISA assay. The in vivo protec-
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the lethal challenge of Hn2 virus.
Results
50% lethal dose (LD50) assay
The EV71 Hn2 strain was isolated from the anal swabs of
one HFMD patient from Henan province, P.R.China in
2009. Sequence analysis showed the Hn2 strain was
closely related to the EV71 strains detected from the Chi-
nese mainland and grouped into genotype C4 [9]. To
determine the 50% lethal viral dosage, two-day-old
BALB/c mice were infected intraperitoneally with 100 μl
of purified Hn2 virus in dilutions, ranging from 1TCID50
(50% tissue culture infectious dose) to 10000TCID50. All
the mice infected with the 1TCID50 and 10TCID50 dilu-
tions survived throughout the 21-day observation period,
although during the first week post-infection they had a
lower average weight than PBS-inoculated mice (data no
shown). With an infective dose of the 100TCID50 dilution
and the 1000TCID50 dilution of virus, all of the mice had
the typical signs and symptoms of EV71 infection, such as
lethargy and paralysis of limbs, within two days post-
infection. At the 100TCID50 and 1000TCID50 dilutions
respectively, 70% (7 of 10) and 20% (2 of 10) of the mice
survived (Fig.1) and lived throughout the 21-day observa-
tion period. With the mice infected with the
10000TCID50 dilution of virus, all developed hind-leg
paralysis and subsequently died within 9 days post-infec-
tion. These results showed that when infected with 100 μl
of 300TCID50 dilution of stock EV71 Hn2 virus by the
intraperitoneal route, 50% of two-day-old BALB/c mice
will die within 9 days post-infection.
Neutralizing antibody assay
After four rounds of panning, seven MAbs were obtained
that reacted with high titer in the Hn2 virus antigen-
coated ELISA assay. The neutralizing activities of the
purified MAbs against EV71 Hn2 virus were analyzed in
Vero cells. Two-fold serial dilutions of each MAb were
incubated together with 100TCID50 Hn2 virus and Vero
cells, and the cyto-pathic effects (CPE) of cells was
observed 72 h post-infection. A convalescent EV71-infect
patient serum was used as a positive control. Among the
seven MAbs, three did not have any neutralizing activity,
beyond that afforded by a 1:4 dilution of serum from the
mock-immunized mice. In contrast, four of the MAbs
protected Vero cells from EV71-induced CPE at dilutions
ranging from 1:4 to 1:64 (Table 1). The MAbs 4D10 and
3B11 showed a neutralizing activity with complete pro-
tection from CPE at dilutions of 1:8 and 1:16, respectively,
and the MAbs 4E8 and 4C6 had the same neutralizing
titer as the convalescent patient serum, in that they all
gave complete protection from EV71-induced CPE at
dilutions up to 1:64.
Identification of monoclonal antibody epitopes by 
peptide-coated ELISA
The epitope-specificity of all four neutralizing monoclo-
nal antibodies was tested by peptide-coated ELISA. Syn-
thetic peptides and E.coli expressed EV71 VP1 were
coated onto the 96-well microtiter plates. Inactived, puri-
fied Hn2 virus was used as a positive control. The results
showed that all of the neutralizing monoclonal antibodies
gave a strong positive signal with inactived Hn2 virus
antigen. Among these positive monoclonal antibodies,
only 4E8 and 4C6 were strongly reactive with the E.coli
expressed VP1 protein. MAbs 4E8 and 4C6 also specifi-
cally reacted with synthetic VP1 peptides P25 (aa240-
250) and P26 (aa250-260)(Table 2). MAb 4C6 showed a
weaker reactivity to the synthetic peptides when com-
pared with 4E8.
Amino acid sequence analysis of EV71 Hn2 VP1
The antigenicity of the EV71 Hn2 VP1 protein was deter-
mined using the method of Kolaskar and Tongaonkar
[16]. Antigenic peptides were predicted based on the
occurrence of amino acid residues in experimentally
known segmental epitopes. This analysis indicated that
there were seven predicted antigenic determinants in the
Hn2 VP1 sequence. One of the predicted antigen
epitopes (aa242-251: KSKYPLVVRI) was located at the C-
terminus of the Hn2 VP1 and corresponded to the syn-
thetic peptide P25 (aa240-250). Sequence alignment indi-
cated that the amino acid sequence of peptide P25
(aa240-250) was less well conserved when compared to
the amino acid sequence represented by peptide P26
(aa250-260), which was totally conserved amongst the 19
EV71 strains from sub-genogroups A to C4 (Fig. 2).
Passive protection test in mice
Two-day-old BALB/c mice were inoculated with the
EV71 Hn2 virus at a dose of 100 LD50 per mouse by the
intraperitoneal (100 μl) route. Then, 24 h later, they were
given 100 μl of MAb 4E8 at different dilutions (1:4, 1:8,
1:16, 1:32, 1:64). The results showed that control mice
that were administered with 4E8 (1:4) antibody remained
healthy and survived throughout the 21-day observation
period. The Hn2 inoculated groups that were adminis-
tered with normal mouse serum had the typical symp-
toms of EV71 infections by day two post-inoculation and,
by day 8 post-inoculation, all the mice had developed
hind leg paralysis and subsequently died. In contrast 69%
of the Hn2 inoculated mice that were administered with a
1:4 dilution of MAb 4E8 survived throughout the 21-day
observation period; The mice administered with 1:8 and
1:16 dilution 4E8 were less protected but, nevertheless
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lated mice administered with a 1:32 dilution 4E8 began to
die a little later than mice administered with normal
mouse serum, they all died within 10 days. Similar to the
inoculated mice administered with normal mouse serum,
all of the inoculated mice administered with 1:64 dilution
4E8 died within 7 days (Fig. 3).
Discussion
The genus Enterovirus, belongs to the family Picornaviri-
dae, and consists of 66 different subtypes, including
polioviruses (PVs), coxsackievirus group A (CVA) and
coxsackievirus group B (CVB), echoviruses, and enterovi-
ruses [17,18]. EV-71 was first described in 1969 during an
outbreak of HFMD in California that was associated with
central nervous system (CNS) complications. EV71 infec-
tions are generally mild, such as HFMD and herpangina,
but occasionally lead to severe diseases with CNS
involvement and clinical symptoms such as aseptic men-
ingitis, poliomyelitis-like paralysis and possibly fatal
encephalitis in neonates [19]. Passive transfer of specific
antibodies has been shown to reduce the severity of viral
infections, including Japanese encephalitis infection [20],
varicella infection [21] and coxsackievirus infection [22].
High-quality MAbs which have specificity, avidity and
neutralizing activity might be a viable treatment option
for EV71 infection in humans.
Previous studies have shown the neutralizing epitope of
EV71 was mainly located at the VP1 protein. So we
selected synthetic VP1 peptides as the antigen to screen a
Figure 1 50% lethal dose (LD50) assay. Two-day-old BALB/c mice were infected intraperitoneally with 100 μl of purified Hn2 virus in dilutions, rang-
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inactived EV71 isolated strain Hn2. Among the MAbs we
characterised, four were shown to have neutralizing
activity, and two can react specifically with the E.coli
expressed VP1 protein and synthetic peptides of VP1.
Experiments are currently in progress to see if the neu-
tralizing MAbs that do not react with VP1 may neutralize
the virus by alternative routes, for example, by preventing
uncoating of the virus by binding to neighbouring capsid
pentamers or by forming aggregates of the viruses as has
been observed in other picornaviruses [23,24].
Computerized antigenicity prediction method as used
in this study can predict antigenic determinants with
about 75% accuracy. Four of the seven epitopes predicted
by this method in the EV71 VP1 protein are located at the
N-terminus, and only one at the C-terminus. This result
is consistent with reports that show the region spanning
amino acids 66-132 of VP1 contains the major dimeriza-
tion domain and cross-reactive enterovirus epitopes [25].
However, there are also reports show that the region
between amino acids 132 and 297 is indispensable, and
contains important conformational epitope which can
react with the convalescent-phase sera [26]. In this study,
we have shown that the MAbs 4C6 and 4E8 can specifi-
cally react with peptides P25(aa240-250) and P26(aa250-
260), one of which overlaps with the predicted C-termi-
nus epitope. Whether the two peptides form a conforma-
tional epitope or just a linear neutralizing epitope
requires futher research. Nevertheless, it is important
that we have shown the 4E8 MAb was able to protect
suckling BALB/c mice from a lethal dose of EV71 Hn2
virus, and, therefore, could be a promising candidate to
be humanized and used for treatment of EV71 infection.
Table 1: In vitro neutralization assays of monoclonal 
antibodies*
Antibodies Neutralization titers








Normal mouse serum <1:4
*50 μl of virus suspension containing 100TCID50 EV71 Hn2 was 
pre-incubated with 50 μl of serial two-fold dilutions of antibodies 
for 30 min before adding to Vero cells in 96-well plates. After 3 
days at 37°C, the titer of neutralizing antibody was read as the 
highest dilution that gave complete protection from CPE.
Table 2: Epitope-specificity assay of monoclonal antibody by ELISA*
Antibody Expressed VP1 Hn2 virus PBS Peptide
4D10 0.400 2.551 0.056 -
3B11 0.338 1.740 0.072 -
4E8 1.820 2.665 0.034 1.374 (P25:aa240-250)
1.448 (P26:aa250-260)
4C6 1.727 2.774 0.080 0.705 (P25:aa240-250)
0.488 (P26:aa250-260)
Normal mouse serum 0.113 0.611 0.045 0.072
*The 96-well microtiter plates were coated with 500 ng of purified EV71 Hn2 virus, E.coli expressed VP1 protein or synthetic VP1 peptide P25 
or P26. Monoclonal antibodies were at a dilution of 1:2000. OD450 nm readings are expressed as the average of of three separate experiments.
Figure 2 Sequence alignment of aa240-260 of EV71 VP1 using 
CLC Main Workbench 5.5 software. Identical residues with the stan-
dard strain BrCr are indicated as dots. Amino acids that differ from the 
consensus sequence (i.e. the majority of amino acids at a position) are 
shaded.
Chang et al. Virology Journal 2010, 7:106
http://www.virologyj.com/content/7/1/106
Page 5 of 7Conclusion
In this study, we generated a set of MAbs by immuniza-
tion BALB/c mice with inactived EV71 isolated strain
Hn2. Among the MAbs we characterised, four were
shown to have neutralizing activity, and two can react
specifically with the E.coli expressed VP1 protein and
synthetic peptides P25(aa240-250) and P26(aa250-260) of
VP1. It is important that we have shown the 4E8 MAb
was able to protect suckling BALB/c mice from a lethal
dose of EV71 Hn2 virus, and, therefore, could be a prom-




Rhabdomyosarcoma cells (RD cell) and Vero cells
(derived from African green monkey kidney) were main-
tained in Dulbecco's modified Eagle's medium (DMEM)
containing 10% fetal bovine serum (FBS) plus 2 mM L-
glutamine, 100U of penicillin, and 100 μg of streptomycin
per ml. The EV71 Hn2 strain was isolated from the anal
swabs of one HFMD patient from Henan province,
P.R.China in 2009. The patient had the typical clinical
symptoms of central nervous system (CNS) involvement,
such as fever, exanthemas, aseptic meningitis, and stiff-
ness of the neck [2]. The Hn2 strain was C4 genotype and
the complete sequence of Hn2 was submitted to Gen-
Bank as accession no. GQ994992.
Virus purification and titer determination
The isolated Hn2 virus were purified by three rounds of
plaque assay in RD cells, then propagated in Vero cells.
The infected cells were harvested and completely lysed by
three cycles of freeze-thaw. The virus from the tissue cul-
ture was purified by precipitation with 7% polyethylene
glycol 8000 and then centrifuged onto a 30% sucrose
cushion at 25,000 g for 4 h. Virus titers were determined
as the median end-point of the tissue culture infectious
dose (TCID50). Serially diluted virus samples (from 10-2 to
10-9) were added to Vero cells in 96-well plates, and eight
Figure 3 In vivo passive protection assay. Groups of two-day-old BALB/c mice were inoculated with EV71 Hn2 virus (100 LD50 per mouse) via the 
intraperitoneal route. Then, 24 h after infection, they were intraperitoneally administered with serially diluted 4E8 monoclonal antibody. Mice in con-
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incubated for 7 days at 37°C, and the TCID50 values were
measured by determining CPE. The TCID50 values were
calculated by the method of Reed-Muench [27].
Determination of LD50 in mice
To determine the 50% lethal dose (LD50), specific-patho-
gen-free, two-day-old BALB/c mice were inoculated
intraperitoneally with 100 μl of serially diluted Hn2 virus.
The survival of the mice was monitored daily, and the
LD50 was calculated as described by Reed-Muench [27].
Production of monoclonal antibody
The purified Hn2 virus was inactivated by heating at 56°C
for 30 min. Groups of 5 adult (4 weeks old) female BALB/
c mice were immunized intraperitoneally in a 50% emul-
sion of Freund's complete adjuvant with 10 μg heat-inac-
tivated EV71 virus. Two booster doses, again in 50%
emulsion with Freund's incomplete adjuvant, were given
at 2 weeks intervals. Two weeks after the last immuniza-
tion, blood samples were obtained from the tail and
tested by enzyme-linked immunosorbent assay (ELISA)
using purified Hn2 virus as antigen. The fusion of spleen
cells with mouse myeloma cell was done as described
[28]. For the production of MAbs, BALB/c mice (4-6
weeks old) were injected intraperitoneally with 106 hybri-
doma cells per mouse. Ten days later, the ascitic fluid was
drained by using an 18-gauge needle. The ascites were
centrifuged at 1,000 g for 10 min to remove cells, MAbs
were purified from collected supernatants by precipita-
tion with 50% saturated ammonium sulfate (pH 7.0) and
dialysised against 0.04M phosphate buffer (pH 6.8). The
MAbs were further purified by using protein A agarose
columns (Bio-Rad Laboratories).
In vitro neutralizing antibody assay
The presence of neutralizing MAbs was determined by in
vitro assay in Vero cell. Monoclonal antibody samples
were incubated at 56°C for 30 min to inactivate the com-
plement. Briefly, 50 μl of two-fold antibody dilutions were
mixed with equal volumes of 100TCID50 of Hn2 virus,
and then the mixture was added to monolayers of Vero
cells in 96-well plates. All serum samples were tested in 8
wells. After 3 days of growth, the titer of neutralizing
antibody was read as the highest dilution that gave com-
plete protection from CPE.
Peptide ELISA assay
Synthetic peptides spanning the entire sequence of the
Hn2 VP1 protein (GenBank accession no. GQ994992)
were synthesized by Invitrogen Company (Beijing,
P.R.China). Each peptide contains 10 amino acid residues
and the levels of antibody reactive to each synthetic pep-
tide were measured by ELISA assay. The 96-well plates
were coated overnight at 4°C with 50 μl of 0.1M carbon-
ate buffer (pH 9.6) containing 500 ng of synthetic peptide
or E.coli expressed EV71 VP1 protein (supplied by Pro-
fessor Hanzhong Wang, Wuhan Institute of Virology,
Chinese Academy of Science). After blocking with 2%
bovine serum albumin (BSA), the plates were incubated
with 50 μl of MAb at the indicated dilutions at 37°C for 1
h and then washed three times with phosphate buffered
saline (PBS) containing 0.1% Tween 20. Horseradish per-
oxidase-conjugated goat anti-mouse IgG antibody (San-
taCruze, USA) was used as secondary antibody at 37°C
for 1 h and the reaction was developed by TMB substrate
(KPL, Gaithersburg, MD). The absorbance at 450 nm was
measured by an ELISA plate reader (Tecan Sunrise,
USA). Each assay was performed three times indepen-
dently.
Passive protection test in mice
Two-day-old BALB/c mice were obtained from the Labo-
ratory Animal Center, Academy of Military Medical Sci-
ences, Beijing. Institutional guidelines for animal care
and use were followed throughout the experiments.
Groups of mice were injected intraperitoneally with 100
μl (100LD50) of Hn2 virus, followed 24 h later by 100 μl of
heat-treated (56°C, 30 min) MAb. Mice in the control
group were injected with the same volume of normal
mice serum. The mice were monitored for clinical symp-
toms, paralysis and death up to day 21 post-inoculation.
Computational analysis of VP1 sequence
Nucleotide sequence and the amino acid sequences were
edited and aligned using CLC Main Workbench 5.5 soft-
ware. The antigenicity of the Hn2 VP1 protein were ana-
lyzed using the method of Kolaskar and Tongaonkar [16],
and antigen epitopes were predicted using the amino acid
sequences of the Hn2 VP1 as query sequences in the
Web: http://www.mifoundation.org.
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